

February 18, 2022<sup>(Revised)</sup>

## Wipro GE Healthcare Pvt. Ltd.: Ratings reaffirmed

### Summary of rating action

| Instrument*            | Previous Rated Amount<br>(Rs. crore) | Current Rated Amount<br>(Rs. crore) | Rating Action                     |
|------------------------|--------------------------------------|-------------------------------------|-----------------------------------|
| Non-Fund based – LC/BG | 400.00                               | 400.00                              | [ICRA]AA (Stable)/A1+; reaffirmed |
| <b>Total</b>           | <b>400.00</b>                        | <b>400.00</b>                       |                                   |

\*Instrument details are provided in Annexure-1

### Rationale

The rating reaffirmation factors in Wipro GE Healthcare Pvt. Ltd.'s (WGE) leading position in the domestic medical equipment industry, supported by its diverse product/services portfolio and strong servicing network. Further, the company derives technological and operational support from its strong parentage of two reputed and leading business conglomerates—General Electric Company (GE) and Wipro Enterprises (P) Limited (WEPL).

WGE financial performance has remained steady in FY2021, with healthy internal accrual generation, a debt-free status and strong coverage metrics. Notwithstanding the company's strong business position, lower offtake of premium medical equipment due to the adverse impact of the pandemic resulted in a moderation of the revenues by 5% in FY2021. Nonetheless, with the pick-up in sales, the company is expected to report a moderate revenue growth in the current fiscal. Also, the company's liquidity position remains strong on the back of healthy internal accrual generation, sizeable cash balance and advances to the GE pool, no debt repayment liability and limited capex requirements.

The ratings, however, are constrained by WGE's moderate profit margins owing to sizeable revenue contribution from the sales of equipment imported by the company, competition in the industry and the susceptibility of its profitability/operations to any adverse changes in Government regulations/policy on the duty structure of imports and any imposition of pricing control on medical equipment sold by the company.

The ratings also factor in WGE's dependence on the GE Group for technology sharing, sourcing of medical equipment, royalty, etc. Any change in these terms can impact the company's operations. Also, the ratings factors in the exposure of profitability to the commodity price fluctuation risk. ICRA has also taken note of the sizeable contingent liabilities, largely arising out of income/wealth tax-related matters.

The Stable outlook reflects ICRA's expectation that WGE will continue to benefit from its established position in the industry, strong parentage and comfortable financial profile; enabling it to sustain its liquidity position.

### Key rating drivers and their description

#### Credit strengths

**Leading player in medical equipment industry** – WGE has an established operational track record and its management/parent company (GE) has extensive experience in the medical equipment industry. Over the years, it has emerged as one the leading players in the domestic medical equipment industry with a wide product portfolio and strong service network. The company's revenue stream is diversified, given its presence in both domestic sales and exports. Apart from domestic sales of medical equipment, WGE exports components as well as provides software/IT and ITeS support services to GE Group companies

globally. As a result, the customer base is well diversified with sales to global Group companies as well as a large number of customers in the domestic market, including reputed private sector corporates and Government organisations.

**Technological and operational support from strong parent entities** – WGE is a joint venture (JV) of two reputed and leading business conglomerates—GE and WEPL—in a 51:49 share, respectively. The company enjoys technological and operational support due to its strong parentage. GE is among the leading players in the global healthcare equipment industry with presence across multiple application/product categories. WEPL is one of the major players in the fast-moving consumer goods (FMCG) business, lighting and office furniture and is also present in the infrastructure and engineering business. WEPL provides strategic and operational business support.

**Comfortable financial profile** – WGE's financial profile is comfortable, with a sizeable scale of operations, healthy internal accrual generation and strong return indicators. The company continues to remain debt-free with robust coverage metrics. Lower offtake of premium medical equipment due to the pandemic is expected to result in a moderate revenue growth and profitability in FY2022. Nevertheless, the company's liquidity position remains comfortable.

### Credit challenges

**Moderate profit margins** – The company has moderate profit margins due to sizeable revenue contribution from the sale (trading in nature) of equipment imported by it, which entails low profitability and competition, especially in healthcare monitoring equipment which has lower ticket value. WGE's operating margins stood at ~7.6% in FY2021. The company's margins in FY2022 are expected to be ~8%, with muted revenue growth expectation.

**Exposure to change in business terms/policies** – WGE's business is also dependent on its terms with the GE Group, related to technology sharing, royalty and transfer pricing arrangements. Any change in these can impact the company's business profile. Also, changes in Government regulations/policy on the duty structure or level of imports and any imposition of pricing control on medical equipment along with raw material price fluctuation can impact the profitability of industry participants, including WGE.

### Liquidity position: Strong

WGE's liquidity is strong, supported by healthy internal accrual generation, sizeable cash balance and no debt repayment liability. ICRA notes that the cash pool balances (~Rs. 1,650 crore as of January 22, 2022), which are part of a common inter-group lending pool, are highly liquid, recallable in 2-3 days' notice, as indicated by the company's management. This, coupled with low/negative working capital intensity, has led to the company's debt-free status. Moreover, cash flow indicators such as fund flow from operations and retained cash flows are expected to remain positive.

### Rating sensitivities

**Positive Factors**- The ratings can be upgraded if the company demonstrates a steady revenue growth and improvement in profit margins on a sustained basis, while maintaining strong liquidity and a comfortable capital structure.

**Negative Factors** – Factors that could lead to a rating downgrade include pressure on revenues and profitability, significant upstreaming of funds to JV partners on a sustained basis squeezing the liquidity, or reduced financial flexibility for being unable to timely recall the cash pool balances, if required. Additionally, any weakening of the linkages with the JV partners could lead to a rating downgrade.

## Analytical approach

| Analytical Approach             | Comments                                            |
|---------------------------------|-----------------------------------------------------|
| Applicable Rating Methodologies | <a href="#">Corporate Credit Rating Methodology</a> |
| Parent/Group Support            | Not applicable                                      |
| Consolidation/Standalone        | Standalone                                          |

## About the company

WGE is a JV of two leading business conglomerates—GE and WEPL—in a 51:49 share. The company was incorporated in March 1990 and is involved in the manufacturing and distribution of medical equipment, besides providing technical support services to GE healthcare global companies. Its manufacturing plants are in Bengaluru (Karnataka).

## Key financial indicators

| WGE                                                  | FY2020  | FY2021  |
|------------------------------------------------------|---------|---------|
| Operating Income (Rs. crore)                         | 5,340.7 | 5,063.8 |
| PAT (Rs. crore)                                      | 301.5   | 283.0   |
| OPBDIT/OI (%)                                        | 5.9%    | 7.6%    |
| RoCE (%)                                             | 26.8%   | 23.4%   |
| Total Outside Liabilities/Tangible Net Worth (times) | 1.3     | 1.5     |
| Total Debt/OPBDIT (times)                            | 0.0     | 0.0     |
| Interest Coverage (times)                            | 8.8     | 17.8    |
| DSCR (times)                                         | 11.6    | 16.9    |

*PAT: Profit after Tax; OPBDIT: Operating Profit before Depreciation, Interest, Taxes and Amortisation; ROCE: PBIT/Avg (Total Debt + Tangible Net Worth + Deferred Tax Liability - Capital Work in Progress); Core ROCE: PBIT/Avg (Total Debt + Tangible Net Worth + Deferred Tax Liability - Capital Work in Progress-investments-loans and advances-liquid investments-cash and bank balance); DSCR: (PBIT + Mat Credit Entitlements - Fair Value Gains through P&L - Non-cash Extraordinary Gain/Loss)/(Interest + Repayments made during the Year), \*Provisional.*

**Status of non-cooperation with previous CRA: Not applicable**

**Any other information: None**

## Rating history for past three years

|   | Instrument             | Current Rating (FY2022)  |                          |                                                   |                       | Chronology of Rating History for the past 3 years |                         |                         |
|---|------------------------|--------------------------|--------------------------|---------------------------------------------------|-----------------------|---------------------------------------------------|-------------------------|-------------------------|
|   |                        | Type                     | Amount Rated (Rs. crore) | Amount Outstanding as on Mar 31, 2021 (Rs. crore) | Date & Rating         | Date & Rating in FY2021                           | Date & Rating in FY2020 | Date & Rating in FY2019 |
|   |                        |                          |                          |                                                   | Feb 18, 2022          | Nov 24, 2020                                      | Aug 30, 2019            | -                       |
| 1 | Non Fund based – BG/LC | Long-term and Short-term | 400.00                   | -                                                 | [ICRA]AA (Stable)/A1+ | [ICRA]AA (Stable)/A1+                             | [ICRA]AA (Stable)/A1+   | -                       |

## Complexity level of the rated instruments

| Instrument             | Complexity Indicator |
|------------------------|----------------------|
| Non Fund based – BG/LC | Very Simple          |

The Complexity Indicator refers to the ease with which the returns associated with the rated instrument could be estimated. It does not indicate the risk related to the timely payments on the instrument, which is rather indicated by the instrument's credit rating. It also does not indicate the complexity associated with analysing an entity's financial, business, industry risks or complexity related to the structural, transactional, or legal aspects. Details on the complexity levels of the instruments, is available on ICRA's website: [Click Here](#)

**Annexure-1: Instrument details**

| ISIN No/Banker's name | Instrument Name        | Date of Issuance / Sanction | Coupon Rate | Maturity Date | Amount Rated (Rs. crore) | Current Rating and Outlook |
|-----------------------|------------------------|-----------------------------|-------------|---------------|--------------------------|----------------------------|
| NA                    | Non Fund based – BG/LC | NA                          | NA          | NA            | 400.00                   | [ICRA]AA (Stable)/A1+      |

**Annexure-2: List of entities considered for consolidated analysis- Not applicable**
**Corrigendum**

**Document dated February 18, 2022 has been corrected with revision as detailed below:**

- 1) The phrase 'moderation in the revenue and profitability in the current fiscal' is replaced by 'moderate revenue growth and profitability in FY2022' in the credit strength section on page no. 2**
- 2) The parent/group support in the analytical approach on page no. 3 has been deleted**

## ANALYST CONTACTS

**Sabyasachi Majumdar**  
+91 124 4545304  
[sabyasachi@icraindia.com](mailto:sabyasachi@icraindia.com)

**Girishkumar Kadam**  
+91 22 6114 3441  
[girishkumar@icraindia.com](mailto:girishkumar@icraindia.com)

**Sanket Thakkar**  
+91 79 4027 1528  
[sanket.thakkar@icraindia.com](mailto:sanket.thakkar@icraindia.com)

**Preet Ludhwani**  
+91 79 4027 1542  
[preet.ludhwani@icraindia.com](mailto:preet.ludhwani@icraindia.com)

## RELATIONSHIP CONTACT

**Jayanta Chatterjee**  
+91 80 4332 6401  
[jayantac@icraindia.com](mailto:jayantac@icraindia.com)

## MEDIA AND PUBLIC RELATIONS CONTACT

**Ms. Naznin Prodhani**  
Tel: +91 124 4545 860  
[communications@icraindia.com](mailto:communications@icraindia.com)

## Helpline for business queries

+91-9354738909 (open Monday to Friday, from 9:30 am to 6 pm)  
[info@icraindia.com](mailto:info@icraindia.com)

## About ICRA Limited:

ICRA Limited was set up in 1991 by leading financial/investment institutions, commercial banks and financial services companies as an independent and professional investment Information and Credit Rating Agency.

Today, ICRA and its subsidiaries together form the ICRA Group of Companies (Group ICRA). ICRA is a Public Limited Company, with its shares listed on the Bombay Stock Exchange and the National Stock Exchange. The international Credit Rating Agency Moody's Investors Service is ICRA's largest shareholder.

For more information, visit [www.icra.in](http://www.icra.in)

## ICRA Limited



### Registered Office

B-710, Statesman House 148, Barakhamba Road, New Delhi-110001

Tel: +91 11 23357940-45



### Branches



© Copyright, 2022 ICRA Limited. All Rights Reserved.

Contents may be used freely with due acknowledgement to ICRA.

ICRA ratings should not be treated as recommendation to buy, sell or hold the rated debt instruments. ICRA ratings are subject to a process of surveillance, which may lead to revision in ratings. An ICRA rating is a symbolic indicator of ICRA's current opinion on the relative capability of the issuer concerned to timely service debts and obligations, with reference to the instrument rated. Please visit our website [www.icra.in](http://www.icra.in) or contact any ICRA office for the latest information on ICRA ratings outstanding. All information contained herein has been obtained by ICRA from sources believed by it to be accurate and reliable, including the rated issuer. ICRA however has not conducted any audit of the rated issuer or of the information provided by it. While reasonable care has been taken to ensure that the information herein is true, such information is provided 'as is' without any warranty of any kind, and ICRA in particular, makes no representation or warranty, express or implied, as to the accuracy, timeliness or completeness of any such information. Also, ICRA or any of its group companies may have provided services other than rating to the issuer rated. All information contained herein must be construed solely as statements of opinion, and ICRA shall not be liable for any losses incurred by users from any use of this publication or its contents.